Last reviewed · How we verify

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
15-Valent Pneumococcal Conjugate Vaccine 15-Valent Pneumococcal Conjugate Vaccine marketed
Meningococcal ACYW135 Polysaccharide Conjugate Vaccine Meningococcal ACYW135 Polysaccharide Conjugate Vaccine phase 3 Polysaccharide conjugate vaccine Meningococcal serogroup A, C, Y, and W-135 polysaccharide capsules Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Jiangsu Province Centers for Disease Control and Prevention · 1 shared drug class
  2. Sanofi Pasteur, a Sanofi Company · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd:

Cite this brief

Drug Landscape (2026). Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-zhifei-lvzhu-biopharmaceutical-co-ltd. Accessed 2026-05-17.

Related